{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["100(9)"],"submitter":["Aperna F"],"pubmed_abstract":["The current study includes 910 patients with systemic mastocytosis (SM) seen at the Mayo Clinic from 1968 to 2024. The primary objective was to examine the prognostic contribution of the International Consensus Classification (ICC), in the context of the Mayo Alliance Prognostic System (MAPS) for SM. World Health Organization classification (WHO-HAEM5) subcategories included (i) indolent/smoldering SM (ISM/SSM; N = 518), (ii) SM associated with another hematological neoplasm (SM-AHN; N = 273), with the latter including both myeloid and lymphoid neoplasms, (iii) aggressive SM (ASM; N = 106), and (iv) WHO-defined mast cell leukemia (MCL; N = 13), which included mast cells with both \"mature\" and \"immature\" morphology. The ICC-defined subcategories were mostly similar with the exception that S"],"journal":["American journal of hematology"],"pagination":["1566-1576"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12326232"],"repository":["biostudies-literature"],"pubmed_title":["Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System."],"pmcid":["PMC12326232"],"pubmed_authors":["Butterfield JH","Pongdee T","Kumar M","Arana Yi CY","Orazi A","Gangat N","Reichard KK","Aperna F","Arber DA","Chen D","Tefferi A","Patnaik MS","Pardanani A","Abdelmagid MG"],"additional_accession":[]},"is_claimable":false,"name":"Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System.","description":"The current study includes 910 patients with systemic mastocytosis (SM) seen at the Mayo Clinic from 1968 to 2024. The primary objective was to examine the prognostic contribution of the International Consensus Classification (ICC), in the context of the Mayo Alliance Prognostic System (MAPS) for SM. World Health Organization classification (WHO-HAEM5) subcategories included (i) indolent/smoldering SM (ISM/SSM; N = 518), (ii) SM associated with another hematological neoplasm (SM-AHN; N = 273), with the latter including both myeloid and lymphoid neoplasms, (iii) aggressive SM (ASM; N = 106), and (iv) WHO-defined mast cell leukemia (MCL; N = 13), which included mast cells with both \"mature\" and \"immature\" morphology. The ICC-defined subcategories were mostly similar with the exception that S","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-04-07T13:30:26.373Z","creation":"2026-04-07T13:18:00.243Z"},"accession":"S-EPMC12326232","cross_references":{"pubmed":["40607735"],"doi":["10.1002/ajh.27764"]}}